AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31861009 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline (oral form)
Number of subjects: 368
Study 31862084 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM)
Number of subjects: 0
Study 31862084 — intervention group
Group type: COMPARATOR
Intervention: Conventional short-term monitoring (STM) strategies
Number of subjects: 0
Study 31862160 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cerebral oxygen saturation monitoring
Number of subjects: 96
Study 31862160 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cerebral oxygen saturation decreases
Number of subjects: 96
Study 31862526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-millimeter fMRI methodology
Number of subjects: 0
Study 31863283 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg starting dose
Number of subjects: 169
Study 31863283 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg starting dose in Del19-positive patients
Number of subjects: 169
Study 31863283 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg starting dose in Asian patients
Number of subjects: 169
Study 31863283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential afatinib and osimertinib
Number of subjects: 169
Study 31863305 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6-specific drugs
Number of subjects: 287
Study 31863744 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular occlusion (EV)
Number of subjects: 310
Study 31863744 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical exclusion (MS)
Number of subjects: 310
Study 31863744 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 310
Study 31865308 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured Resting Energy Expenditure (REE)
Number of subjects: 27
Study 31865308 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone and interleukin-6 plasma levels
Number of subjects: 27
Study 31865308 — intervention group
Group type: EXPERIMENTAL
Intervention: REE-to-lean body mass (LBM) ratio
Number of subjects: 27
Study 31865308 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 27
Study 31865308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional markers (transthyretin)
Number of subjects: 27
Study 31865389 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with LVWT <6 mm (≤20% group)
Number of subjects: 54
Study 31865389 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with LVWT 20-50%
Number of subjects: 54
Study 31865389 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with LVWT ≥50%
Number of subjects: 54
Study 31865389 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with LVWT ≥25%
Number of subjects: 54
Study 31865391 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent-onset paroxysmal or persistent AF
Number of subjects: 392
Study 31865391 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume
Number of subjects: 392
Study 31865391 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 392
Study 31865391 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor-1 (PAI-1)
Number of subjects: 392
Study 31865391 — intervention group
Group type: EXPERIMENTAL
Intervention: AF progression
Number of subjects: 392
Study 31865481 — intervention group
Group type: EXPERIMENTAL
Intervention: BOMET-QoL-10 questionnaire
Number of subjects: 172
Study 31865481 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for pain
Number of subjects: 172
Study 31865481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived health status item
Number of subjects: 172
Study 31865734 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-oxygen therapy for 0.5, 1, and 2 months
Number of subjects: 3
Study 31865771 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVH and elevated cardiac biomarkers
Number of subjects: 46
Study 31865771 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46
Study 31865797 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in NT-proBNP level over 3.2 years
Number of subjects: 4563
Study 31865965 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31866281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg orally twice per day in 28-day cycles until disease progression or unacceptable toxicity
Number of subjects: 106
Study 31866281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 106
Study 31866516 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52-mg intrauterine system
Number of subjects: 1513
Study 31866855 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 17
Study 31866924 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-Based Telerehabilitation Intervention
Number of subjects: 0
Study 31867125 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-Anterior Mobilization (PAM)
Number of subjects: 12
Study 31867125 — intervention group
Group type: COMPARATOR
Intervention: Anterior-Posterior Mobilization (APM)
Number of subjects: 12
Study 31867430 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 31867430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31867437 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to a cardiology department
Number of subjects: 3677
Study 31867437 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not involving a cardiology department)
Number of subjects: 3677
Study 31867564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab therapy
Number of subjects: 0
Study 31867564 — intervention group
Group type: COMPARATOR
Intervention: Minimum clinically important difference (MCID) of 0.22
Number of subjects: 0
Study 31868043 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma shared decision making (SDM) intervention
Number of subjects: 10
Study 31868121 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations (PEq) for RMR estimation
Number of subjects: 56
Study 31868997 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (58%)
Number of subjects: 2063
Study 31868997 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (32%)
Number of subjects: 2063
Study 31868997 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L visual analogue score
Number of subjects: 2063
Study 31868997 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-morbidities
Number of subjects: 2063
Study 31868997 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG performance score
Number of subjects: 2063
Study 31869400 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30)
Number of subjects: 929
Study 31869400 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab administration
Number of subjects: 929
Study 31869400 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline treatment (86% epirubicin, 7% doxorubicin)
Number of subjects: 929
Study 31869400 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 929
Study 31869407 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial thrombosis after MPN diagnosis
Number of subjects: 647
Study 31869407 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial thrombosis
Number of subjects: 647
Study 31869413 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with conditioning consisting of carmustine, etoposide, cytarabine, melphalan, and alemtuzumab.
Number of subjects: 31
Study 31869413 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with donor lymphocyte infusions (DLI) for mixed chimerism or residual or relapsed disease.
Number of subjects: 31
Study 31869413 — intervention group
Group type: EXPERIMENTAL
Intervention: Allo-HSCT
Number of subjects: 31
Study 31869417 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor and host HLA both expressed ligands for donor inhibitory KIRs
Number of subjects: 390
Study 31869417 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells expressing 3 inhibitory receptors (KIR2DL1/2DL3/3DL1)
Number of subjects: 390
Study 31869417 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor and host HLA both expressed all ligands for donor inhibitory KIRs
Number of subjects: 390
Study 31870231 — intervention group
Group type: EXPERIMENTAL
Intervention: High ordering cardiologists (top tertile of rA transthoracic echocardiogram ordering frequency)
Number of subjects: 1677
Study 31870231 — intervention group
Group type: COMPARATOR
Intervention: Low ordering cardiologists (bottom tertile of rA transthoracic echocardiogram ordering frequency)
Number of subjects: 1677
Study 31870336 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual sleep assessment
Number of subjects: 300
Study 31870336 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity risk behaviors assessment
Number of subjects: 300
Study 31870336 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection over two years (8, 16, and 24 months after Time 1)
Number of subjects: 300
Study 31870369 — intervention group
Group type: EXPERIMENTAL
Intervention: CHU9D-DK (using UK adult algorithm)
Number of subjects: 272
Study 31870369 — intervention group
Group type: EXPERIMENTAL
Intervention: CHU9D-DK (using Australian adolescent algorithm)
Number of subjects: 272
Study 31870369 — intervention group
Group type: EXPERIMENTAL
Intervention: PedsQL
Number of subjects: 272
Study 31870369 — intervention group
Group type: EXPERIMENTAL
Intervention: CHU9D-DK
Number of subjects: 272
Study 31870408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport physical activity (PA)
Number of subjects: 9218
Study 31870408 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure physical activity (PA)
Number of subjects: 9218
Study 31870408 — intervention group
Group type: COMPARATOR
Intervention: Transport PA by sex
Number of subjects: 9218
Study 31870408 — intervention group
Group type: COMPARATOR
Intervention: Leisure PA by sex
Number of subjects: 9218
Study 31870408 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of not meeting PA recommendations for transport
Number of subjects: 9218
Study 31870408 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of not meeting PA recommendations for leisure
Number of subjects: 9218
Study 31870408 — intervention group
Group type: COMPARATOR
Intervention: Sitting time by demographic factors
Number of subjects: 9218
Study 31870462 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-reported internalizing symptoms
Number of subjects: 750
Study 31870462 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's self-reported depressive symptoms
Number of subjects: 750
Study 31870462 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's self-reported symptoms of anxiety
Number of subjects: 750
Study 31870462 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-rated internalizing symptoms
Number of subjects: 750
Study 31870462 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's self-reported symptoms of depression
Number of subjects: 750
Study 31870461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Number of subjects: 739
Study 31870689 — intervention group
Group type: EXPERIMENTAL
Intervention: F/B-EVAR with multistaged approach
Number of subjects: 80
Study 31870883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years
Number of subjects: 83
Study 31870951 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA-MRI
Number of subjects: 171
Study 31870951 — intervention group
Group type: EXPERIMENTAL
Intervention: HBA-MRI
Number of subjects: 171
Study 31871217 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional folate
Number of subjects: 311
Study 31871448 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 91
Study 31871455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutrition and lifestyle intervention (6-month intervention with group education, cooking demonstrations, motivational interviewing, online resources)
Number of subjects: 29
Study 31871784 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental exposure to stressors related to community safety
Number of subjects: 273
Study 31871787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and Zeaxanthin supplementation for one year
Number of subjects: 47
Study 31871787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31872062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0
Study 31872152 — intervention group
Group type: EXPERIMENTAL
Intervention: Family economic strengthening (matched savings accounts, financial management training, small business development)
Number of subjects: 702
Study 31872152 — intervention group
Group type: COMPARATOR
Intervention: Bolstered usual care (SOC) (enhanced adherence sessions)
Number of subjects: 702
Study 31872157 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated primary care intervention
Number of subjects: 0
Study 31872157 — intervention group
Group type: COMPARATOR
Intervention: Usual care (behavioral health only)
Number of subjects: 0
Study 31872324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-tracer PET/CT imaging
Number of subjects: 31
Study 31872928 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent pazopanib at a dose of 800 mg daily
Number of subjects: 34
Study 31874051 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled severe asthma (SA)
Number of subjects: 670
Study 31874051 — intervention group
Group type: COMPARATOR
Intervention: Controlled severe asthma (SA)
Number of subjects: 670
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated interferon signature (IRG-S)
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophilic panniculitis
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal ganglia calcifications
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial lung disease
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Myositis
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS)
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: LRBA mutations
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: IKBKG splice variants
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMD9L mutations
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in SAMHD1, TREX1, PSMB8, or PSMG2
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-MDA5 autoantibody-positive juvenile dermatomyositis
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclassified patients
Number of subjects: 66
Study 31874111 — intervention group
Group type: EXPERIMENTAL
Intervention: IRG-S
Number of subjects: 66
Study 31874154 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire at 1 week and at 1, 3, 6, and 12 months after injury
Number of subjects: 4239
Study 31874588 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class analysis of family social environment typologies
Number of subjects: 0
Study 31874901 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective histopathological examination based on macroscopic assessment by the surgeon
Number of subjects: 0
Study 31874901 — intervention group
Group type: COMPARATOR
Intervention: Routine histopathological examination
Number of subjects: 0
Study 31874901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of selective histopathological examination
Number of subjects: 0
Study 31874899 — intervention group
Group type: COMPARATOR
Intervention: SDMs who were not approached for organ donation
Number of subjects: 60
Study 31874899 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMs who were approached and consented to donate
Number of subjects: 60
Study 31874899 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMs who were approached but did not consent to donate
Number of subjects: 60
Study 31875196 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d for 14 weeks
Number of subjects: 456
Study 31875196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 31875881 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal density testing (MMDT) framework applied to MRI data
Number of subjects: 0
Study 31875881 — intervention group
Group type: EXPERIMENTAL
Intervention: MMDT framework
Number of subjects: 0
Study 31875915 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) for 16 weeks
Number of subjects: 106
Study 31875931 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 2 mg/day
Number of subjects: 0
Study 31875931 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 4 mg/day
Number of subjects: 0
Study 31875931 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study 31876107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus combined with oral metronomic therapy (twice daily celecoxib, alternating etoposide and cyclophosphamide every three weeks)
Number of subjects: 18
Study 31876124 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance myography (EIM) at 100 kHz resistance in ambulatory boys
Number of subjects: 44
Study 31876124 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance myography (EIM) at 100 kHz resistance in non-ambulatory boys
Number of subjects: 44
Study 31876124 — intervention group
Group type: EXPERIMENTAL
Intervention: EIM 100 kHz resistance values
Number of subjects: 44
Study 31876124 — intervention group
Group type: EXPERIMENTAL
Intervention: EIM
Number of subjects: 44
Study 31876911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily for a median of 41 months (range 0.2-58 months)
Number of subjects: 134
Study 31876911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily
Number of subjects: 134
Study 31876927 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus neuropeptide Y (CS NPY) levels ≥ 130 pg/mL
Number of subjects: 105
Study 31876927 — intervention group
Group type: COMPARATOR
Intervention: Control group (organ donors)
Number of subjects: 105
Study 31877507 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at in-laboratory polysomnography (iPSG)
Number of subjects: 122
Study 31877507 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (demographic, lifestyle, and cognitive status)
Number of subjects: 122
Study 31878890 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete BA configuration
Number of subjects: 34
Study 31878890 — intervention group
Group type: COMPARATOR
Intervention: Incomplete BA configuration
Number of subjects: 34
Study 31878890 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal BA configuration
Number of subjects: 34
Study 31878890 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal BA configuration
Number of subjects: 34
Study 31878895 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus infection in pregnant women
Number of subjects: 0
Study 31878895 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus infection in children
Number of subjects: 0
Study 31878895 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus infection in symptomatic rash/fever illness
Number of subjects: 0
Study 31878895 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus infection
Number of subjects: 0
Study 31878938 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 high (≥ 25% TC)
Number of subjects: 412
Study 31878938 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 ≥ 10% TC
Number of subjects: 412
Study 31878938 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 ≥ 50% TC
Number of subjects: 412
Study 31879324 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Track® CMV (cytomegalovirus-specific cellular immunity measured using a standardized IFN-γ ELISpot assay)
Number of subjects: 175
Study 31879328 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry positivity for occult central nervous system disease
Number of subjects: 240
Study 31879328 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system disease negative status
Number of subjects: 240
Study 31879328 — intervention group
Group type: EXPERIMENTAL
Intervention: Status of manifest and occult central nervous system disease positivity
Number of subjects: 240
Study 31879782 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg
Number of subjects: 109
Study 31879814 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 9
Study 31879838 — intervention group
Group type: EXPERIMENTAL
Intervention: General population after ICH episode
Number of subjects: 3594
Study 31879838 — intervention group
Group type: COMPARATOR
Intervention: Complex chronic patients after ICH episode
Number of subjects: 3594
Study 31879838 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 80 years
Number of subjects: 3594
Study 31879838 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 3594
Study 31879838 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 3594
Study 31879838 — intervention group
Group type: COMPARATOR
Intervention: Complex chronic patients
Number of subjects: 3594
Study 31879838 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal validation of the model
Number of subjects: 3594
Study 31879838 — intervention group
Group type: COMPARATOR
Intervention: External validation in complex chronic patients
Number of subjects: 3594
Study 31879842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg/28 days
Number of subjects: 0